Excitement is building around a new weight loss drug, CagriSema, which is expected to surpass the effects of popular drugs ...
Novo Nordisk, after mulling the implications of a phase 3 fail, has given up on a late-stage kidney drug acquired in a $1.3 ...
“Honestly, I’m quite alarmed by what we see in the U.S. now,” Novo Nordisk President and CEO Lars Fruergaard Jorgensen told ...
Novo Nordisk chief financial officer Karsten Munk Knudsen said on Wednesday the company was aware of reports of 10 deaths and ...
Data reported earlier Monday from Viking Therapeutics (NASDAQ:VKTX) on its weight loss medicine VK2735 indicates that Novo Nordisk (NVO ... also has another pill, amycretin.